首頁 › 膠質母細胞瘤 › 田納西州 › Nashville
Nashville, TN 的 膠質母細胞瘤 臨床試驗
9 項針對 膠質母細胞瘤 的研究正在 Nashville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
招募中1/2 期
- SCRI Oncology Partners, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Vanderbilt-Ingram Cancer Center, Nashville
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
招募中2 期
- Vanderbilt-Ingram Cancer Center, Nashville
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
招募中早期第 1 期
- Vanderbilt University Medical Center, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
招募中1 期
- Sarah Cannon, SCRI Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Tennessee Oncology, Nashville
其他城市的 膠質母細胞瘤 試驗
- New York City, NY30 項研究
- Boston, MA28 項研究
- Houston, TX26 項研究
- Los Angeles, CA24 項研究
- Durham, NC20 項研究
- San Francisco, CA17 項研究
- Chicago, IL15 項研究
- Washington, DC15 項研究
- Columbus, OH14 項研究
- Miami, FL14 項研究
- Rochester, MN13 項研究
- Jacksonville, FL13 項研究
Nashville 的其他研究
- 非小細胞肺癌97 項研究
- 乳癌81 項研究
- 轉移性癌症70 項研究
- 大腸直腸癌69 項研究
- 癌症（所有類型）65 項研究
- 卵巢癌49 項研究
- 前列腺癌43 項研究
- 肺癌40 項研究
- 頭頸部鱗狀細胞癌39 項研究
- 胰臟癌39 項研究
- 子宮內膜癌38 項研究
- 黑色素瘤33 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。